Probiotic Bifidobacterium Breve BBr60 Boosts GLP-1 and Other Metabolic Peptides in People With Obesity

A randomized, double-blind, placebo-controlled trial enrolled 75 individuals with obesity (BMI ≥ 28), with 65 completing the study (33 BBr60, 32 placebo). The intervention group received 10 billion CFU of Bifidobacterium breve BBr60 daily for 12 weeks. All participants received standardized nutritional counseling (~1800 kcal/day, 25g fiber) with weekly phone check-ins. Gut microbiota was analyzed by 16S sequencing, fecal short-chain fatty acids by GC-MS, and serum hormones and cytokines by ELISA.

GLP-1 receptor agonist drugs like semaglutide and tirzepatide are revolutionary for obesity, but they require injections or expensive prescriptions. This study suggests that specific probiotics can naturally boost the body's own production of GLP-1 and other metabolic peptides by improving gut health. This could offer a complementary, accessible approach to improving metabolic function in obesity.

The connection between gut bacteria, short-chain fatty acids, and metabolic hormones is a rapidly growing field. This study provides human clinical trial evidence linking a specific probiotic to increased endogenous GLP-1 and other peptide hormones through a defined mechanistic pathway. As GLP-1-based therapies dominate the obesity treatment landscape, understanding how to naturally boost GLP-1 through gut health could complement pharmacological approaches.

The sample size was modest (65 completers). The study was 12 weeks — long-term effects and sustainability of metabolic improvements are unknown. While many peptide hormones increased, the abstract doesn't report actual weight loss or body fat changes, making it hard to assess clinical significance. The ~1800 kcal/day dietary counseling may have contributed to results in both groups. The specific mechanisms connecting butyrate to each hormone require further investigation.